ViroPharma inks $164M deal to buy orphan drug biotech

Exton, PA-based ViroPharma has forged a deal to buy Sweden's DuoCort Pharma for $33.6 million in cash and a package of $131 million in milestones, provided it can win EC approval of Plenadren, a orphan treatment for adrenal insufficiency. The deal is designed to expand ViroPharma's orphan drug portfolio without adding a lot of risk to the books. The drug is up for a formal EC decision by the end of this year. "Plenadren will be an important drug for patients with Addison's disease and other chronic adrenal insufficiencies, and is the first new drug in this therapeutic area in over 50 years," said Vincent Milano. Release

Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.